Preventing Medicare Telefraud Act
- Bill Number
- H.R. 1785
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-03-03: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2025-03-27T15:12:11Z
AI-Generated Summary
Purpose of the Legislation
The "Preventing Medicare Telefraud Act" (H.R. 1785) aims to reduce potential fraud and abuse in Medicare's telehealth services by imposing stricter requirements for ordering high-cost medical items and conducting audits on high-volume telehealth prescribers. It focuses on ensuring that certain expensive durable medical equipment (DME) and laboratory tests are not ordered solely through remote consultations without prior in-person care, while also mandating proper identification for billing telehealth services.
Key Provisions
- Restrictions on High-Cost Durable Medical Equipment (DME):
- Medicare will not pay for high-cost DME (e.g., items like wheelchairs or oxygen equipment that meet a cost threshold defined by the Centers for Medicare & Medicaid Services, or CMS) if ordered via telehealth unless the prescribing physician or practitioner has provided at least one in-person service to the patient in the previous 6 months.
- This rule applies starting 180 days after enactment.
- CMS must define what qualifies as "high-cost DME."
- Audits for High-Volume Telehealth DME Prescribers:
- Starting 6 months after enactment, Medicare administrative contractors (entities that process Medicare claims) must review claims from the prior 12 months to identify physicians or practitioners who prescribed DME via telehealth for at least 90% of their cases.
- Identified providers will face audits of all their DME claims to check compliance with Medicare coverage rules.
- Restrictions on High-Cost Laboratory Tests:
- Similar to DME, Medicare will not pay for high-cost lab tests (defined by CMS, such as advanced genetic or imaging tests) ordered via telehealth without an in-person service in the prior 6 months.
- This applies starting 180 days after enactment.
- Audits for High-Volume Telehealth Lab Test Prescribers:
- Medicare contractors must periodically review prior 12-month claims to flag physicians or practitioners prescribing lab tests via telehealth for 90% or more of cases.
- Flagged providers will be audited for all lab test claims to ensure they meet Medicare standards.
- Billing Requirements for Telehealth Services:
- Starting 180 days after enactment, claims for separately billable telehealth services (those charged independently) must include the prescriber's National Provider Identifier (NPI), a unique ID number assigned to healthcare providers for billing and tracking purposes.
Significant Changes to Existing Law
- Amends Section 1834(a)(1)(E) of the Social Security Act to add new rules limiting telehealth orders for high-cost DME and mandating audits.
- Adds paragraphs to Section 1834A(b) for similar restrictions and audits on high-cost lab tests.
- Modifies Section 1834(m) to require NPI submission for telehealth billing, enhancing traceability and preventing anonymous or improper claims.
These changes build on existing Medicare telehealth flexibilities (expanded during the COVID-19 pandemic) by introducing safeguards against over-reliance on remote care for costly items, without fully prohibiting telehealth.
Potential Impacts
- On Government Agencies: CMS and Medicare administrative contractors will face increased administrative burdens from defining high-cost items, conducting reviews, and performing audits, potentially raising costs for oversight but aiming to reduce fraudulent payments and save Medicare funds.
- On Citizens (Medicare Beneficiaries): Patients may experience delays or barriers in accessing high-cost DME or lab tests through telehealth, requiring more in-person visits, which could affect convenience, especially for those in rural or mobility-limited areas. However, it may improve care quality by ensuring physical evaluations.
- On International Relations: No direct impacts, as the bill is limited to U.S. domestic Medicare policy.
Main Stakeholders Affected
- Healthcare Providers: Physicians and practitioners using telehealth, particularly those prescribing high volumes of DME or lab tests, will need to adjust practices to include in-person visits and comply with audits and billing rules; non-compliance could lead to denied payments or penalties.
- Medicare Beneficiaries: Elderly and disabled individuals relying on Medicare-covered DME and tests may see changes in how they receive care.
- Medicare Program Administrators: CMS and contractors will implement and enforce the new rules, affecting claim processing and fraud detection.
- Medical Equipment and Lab Suppliers: Could see shifts in order volumes due to prescribing restrictions, potentially reducing telehealth-driven demand.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: Strengthens Medicare's fraud prevention under existing anti-abuse laws (e.g., False Claims Act) by mandating audits and documentation, but could lead to disputes over CMS's definitions of "high-cost" items if challenged in court for vagueness.
- Constitutional Implications: None significant; the bill operates within Congress's authority to regulate federal programs like Medicare and does not infringe on free speech, privacy, or due process rights directly.
- Political Implications: Balances telehealth expansion (popular for accessibility) with fraud concerns, potentially sparking debate between rural health advocates (favoring telehealth) and fiscal conservatives (prioritizing cost controls). As an amendment to the Social Security Act, it could influence broader healthcare policy discussions on post-pandemic telehealth regulations.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Recent Actions
- 2025-03-03: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-03-03: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-03-03: Introduced in House
- 2025-03-03: Introduced in House
Bill Versions
- Preventing Medicare Telefraud Act — issued 2025-03-03 — PDF (7 pages)